Zoetis Announces U.S. Label Update for Librela® (bedinvetmab injection), a Treatment to Control Canine Osteoarthritis (OA) Pain

Since its launch in Europe four years ago, Librela has improved the lives of millions of dogs suffering from OA pain. With nearly 25 million doses1 distributed globally, no individual adverse event sign has been reported at a rate higher than rare, as defined by the European Medicines Agency (EMA) – representing less than 10 occurrences per 10,000 treated animals (where one dose equals one treated animal)2 .